Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer to talk quarterly results, what sectors it is seeing strength in, its recent acquisition of Verona Pharma and more. Got a ...

Good afternoon, everybody. We're going to get started here. But I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. I'm very pleased to be hosting Merck this afternoon. From the company, we ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its post-Keytruda future with what it foresees as a host of major sales ...

All right. We're just about at time. So let's keep moving with our next session with Merck. I'm very excited to have Rob Davis, CEO; and Dean Li, EVP Research Labs. Thank you both for being with us ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral pipeline with a Phase III drug designed to ...

(Bloomberg) -- Merck & Co. is splitting its main pharmaceutical unit in two in an effort to better highlight the parts of the business that are growing, as it stares down a patent cliff for its ...

Robert Davis, Merck CEO, joins 'Mad Money' host Jim Cramer to talk quarterly results, global sales growth, recent acquisitions, and more. Got a confidential news tip? We want to hear from you. Sign up ...